Copyright
©The Author(s) 2025.
World J Gastroenterol. Jun 28, 2025; 31(24): 108298
Published online Jun 28, 2025. doi: 10.3748/wjg.v31.i24.108298
Published online Jun 28, 2025. doi: 10.3748/wjg.v31.i24.108298
Figure 2 After propensity score-matching analysis of progression-free survival and overall survival.
A: After propensity score-matching analysis of progression-free survival (ratio = 4); B: After propensity score-matching analysis of overall survival (ratio = 4).
- Citation: Gao Z, Wang XY, Shen ZG, Liu JH, Wang XY, Wu SK, Jin X. Real-world comparison of chemotherapy plus bevacizumab with or without immunotherapy as first-line therapy in colorectal cancer. World J Gastroenterol 2025; 31(24): 108298
- URL: https://www.wjgnet.com/1007-9327/full/v31/i24/108298.htm
- DOI: https://dx.doi.org/10.3748/wjg.v31.i24.108298